Affiliation:
1. The University of British Columbia
Abstract
Abstract
Background
Immune checkpoint inhibitors (ICIs) have expanded the arsenal of cancer therapeutics over the last decade but are associated with a spectrum of immune-related adverse events (irAEs), including inflammatory arthritis. While these complications are increasingly recognized in the adult population, no cases of inflammatory arthritis irAEs have been reported in the pediatric literature.
Case Presentation
A 14-year-old female with metastatic epithelioid mesothelioma was referred to the pediatric rheumatology clinic after developing progressive inflammatory joint pain in her bilateral shoulders, hips, and small joints of hands following the second cycle of Nivolumab and Ipilimumab. Initial examinations showed bilateral shoulder joint line tenderness, positive FABERs test bilaterally, tenderness over bilateral greater trochanters, and bilateral second PIP effusions. Her serological profile was notable for positive HLA-B27, positive anti-CCP, negative Rheumatoid Factor, and negative ANA. PET-CT scan performed for disease response following immunotherapy showed symmetric increased metabolic activity primarily involving the supraspinatus, gluteus medius and minimus, and semimembranosus tendon insertions. Her presentation was consistent with a grade 1 irAE that worsened to a grade 2 irAE despite NSAID therapy, prompting a short course of oral prednisolone. She achieved clinical remission of her mesothelioma following six cycles of Nivolumab and Ipilimumab and her inflammatory arthritis was controlled on Celebrex monotherapy.
Conclusions
To our knowledge, this is the first pediatric case of ICI-induced inflammatory arthritis and enthesitis. This case highlights the importance of increasing awareness of diagnosis and management of irAEs in children.
Publisher
Research Square Platform LLC
Reference10 articles.
1. Nivolumab for the Treatment of Advanced Pediatric Malignancies;Marjańska A;Anticancer Res,2020
2. Immune-related adverse events of checkpoint inhibitors;Ramos-Casals M;Nat Rev Dis Primers,2020
3. Health UDo, Services H. Common terminology criteria for adverse events (CTCAE) version 5.0. 20172017 October 23. 2023. Available from: ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
4. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist;Jamal S;J Rheumatol,2020
5. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies;Buder-Bakhaya K;Cancer Immunol Immunother,2018